Our exciting collaboration enables our research and early development group to apply state-of-the-art organ-on-a-chip technology in the modeling of IBD and HBV. These models have the potential to improve our understanding of disease biology and transform
The 'I' in MIMETAS
'
Tackling challenges together.
What customers say
'
"The OrganoReady Colon Caco-2, combined with the OrganoTEER, have become our gold standard in vitro model for the screening of intestinal barrier disruptors at SIAF. "
What customers say
'
The OrganoPlate Caco-2 model is for us, at Merck, the most suitable platform offering at the same time scalability, speed, robustness, ease of handling, with low compound needs.
Mimetas' tumor infiltration platform demonstrated a therapeutic effect of our compound on immune cell recruitment: we’re very excited by these proof of concept data
The 'I' in MIMETAS
Jos Joore
CEO
'
We want to empower research on complex tissue biology.
Often you have to compromise it’s either the throughput or it’s the complexity of the model. Getting both in the same platform… no other platform can do that!
We were able to measure cell barrier permeabilities in a lung-on-a-chip model demonstrating superior sensitivity and translatability than any other lung cell model we tried before. It was also very easy to scale up our data generation workflow.
The 'I' in MIMETAS
Henriëtte Lanz
Director of Model Development
'
It should be mandatory to socialize with colleagues.
May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy